When can we anticipate the availability of a commercially viable dengue vaccine
Evaluation of the timeline for the potential commercial release of a dengue vaccine by mid-2026.
- Dengue vaccine development is a complex process that involves preclinical studies, multiple phases of clinical trials, regulatory approval, and production scale-up.
- Current frontrunners in dengue vaccine development are Takeda, Sanofi Pasteur, and the Butantan Institute.
- Takeda’s TAK-003 and Sanofi Pasteur’s Dengvaxia are in advanced stages of clinical trials.
- Based on the current progress, a potential timeline for commercial release of a dengue vaccine could be by mid-2026.
- However, this timeline is subject to factors such as successful completion of clinical trials, regulatory approvals, production scaling, and market availability.
Answered
a year ago